Benserazide, an Inhibitor of Peripheral Kynurenine Metabolism, Attenuates Olanzapine-Induced Weight Gain, Insulin Resistance, and Dyslipidemia in C57Bl/6j Mice
- 14 Downloads
Schizophrenia (Sz) patients, especially treated with atypical antipsychotics, are at high risk of the development of metabolic syndrome that increases morbidity and mortality and impairs compliance with treatment. Mechanism of the high association of metabolic syndrome with the use of atypical antipsychotics is not clear. Literature and our data suggest that chronic inflammation- or stress-induced dysregulation of the peripheral down-stream kynurenine (Kyn) metabolism, shared by both Sz and metabolic syndrome, contributes to the development of metabolic syndrome in Sz patients treated with atypical antipsychotics. Correction of dysregulation of the peripheral down-stream metabolism of Kyn would prevent/treat metabolic syndrome. This is a pre-clinical trial of the effect of benserazide (BRZ), an inhibitor of the key enzymes of Kyn metabolism, on olanzapine-induced mouse model of metabolic syndrome. Olanzapine is one of the most effective atypical antipsychotics but has high potential to induce metabolic syndrome. Olanzapine (4 mg/kg, p.o) and/or BRZ (100 mg/day, p.o.) were administered to 6-week-old C57Bl/6 female mice, 5 days/week, for 10 weeks. The study was approved by the Tufts Medical Center Institutional Animal Care and Use Committee. BRZ attenuated olanzapine-induced excessive weight gain, impairment of glucose tolerance, and elevation of plasma cholesterol and triglycerides. Present results suggest that peripheral down-stream Kyn metabolism is a new target for prevention/treatment of olanzapine-induced metabolic syndrome. BRZ has a high translational potential as medication already approved for human use.
KeywordsBenserazide Olanzapine Obesity Insulin resistance Kynurenic acid Anthranilic acid Metabolic syndrome
Nicotinamide adenine dinucleotide.
Compliance with Ethical Standards
Conflict of Interest
The results discussed here are the subject of a pending patent application.
P. Summergrad is a non-promotional speaker for CME outfitters, Inc., and Pharmasquire and receives royalties from Springer, Harvard University Press, and the American Psychiatric Publishing. He is a consultant for Mental Health Data Services, Inc. and Quartet Health, Inc. The other author declares no conflict of interest.
- 1.Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 19(Suppl 1):1–93Google Scholar
- 3.Chouinard VA, Pingali SM, Chouinard G, Henderson DC, Mallya SG, Cypess AM, Cohen BM, Öngür D (2016) Factors associated with overweight and obesity in schizophrenia, schizoaffective and bipolar disorders. Psychiatry Res 237:304–310. https://doi.org/10.1016/j.psychres.2016.01.02 CrossRefGoogle Scholar
- 6.Oxenkrug G (2015) 3-hydroxykynurenic acid and type 2 diabetes: implications for aging, obesity, depression, Parkinson’s disease and schizophrenia. In: Engin A, Engin AB (eds) Tryptophan metabolism: implications for biological processes, health and diseases, molecular and integrative toxicology. Springer International Publishing, Switzerland, pp. 173–195. https://doi.org/10.1007/978-3-319-15630-9_8 Google Scholar
- 7.Oxenkrug G, van der Hart M, Roeser J, Summergrad P (2016) Anthranilic acid: a potential biomarker and treatment target for schizophrenia. Ann Psychiatry Ment Health 4:1059–1062Google Scholar
- 17.Wolowczuk I, Hennart B, Leloire A, Bessede A, Soichot M, Taront S, Caiazzo R, Raverdy V et al (2012) Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone. Am J Phys Regul Integr Comp Phys 303:R135–R143Google Scholar
- 18.Favennec M, Hennart B, Caiazzo R, Leloire A, Yengo L, Verbanck M, Arredouani A, Marre M et al (2015) The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation. Obesity (Silver Spring) 23:2066–2074. https://doi.org/10.1002/oby.21199 CrossRefGoogle Scholar
- 20.Moyer BJ, Rojas IY, Kerley-Hamilton LS, Harlett HF, Nemani KY, Trask HW, West RJ, Lupien LE et al (2016) Inhibition of aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFß, and IDO1. Toxicol Appl Pharmacol 300:13–24CrossRefGoogle Scholar
- 21.DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzana EM, Omiecinski CJ, Perdew GH (2010) Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci 115:8997CrossRefGoogle Scholar